康众医疗(688607) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥52,969,765.80, representing a year-on-year increase of 5.69%[5] - Total revenue for Q1 2024 was CNY 52,969,765.80, an increase of 5.8% compared to CNY 50,118,994.79 in Q1 2023[18] - Operating profit for Q1 2024 was CNY 2,038,345.06, a significant improvement from a loss of CNY 7,002,035.49 in Q1 2023[19] - Net profit for Q1 2024 reached CNY 1,190,756.45, compared to a net loss of CNY 6,670,634.06 in the same period last year[19] - The company reported a comprehensive income of CNY 749,772.97 in Q1 2024, recovering from a loss of CNY 7,755,168.80 in Q1 2023[20] - The company incurred total operating costs of CNY 53,280,817.38 in Q1 2024, down from CNY 58,245,493.04 in Q1 2023, reflecting cost management efforts[18] Cash Flow - The net cash flow from operating activities was negative at ¥2,277,561.69[5] - Cash flow from operating activities showed a net outflow of CNY 2,277,561.69, an improvement from a net outflow of CNY 16,390,474.84 in Q1 2023[24] - The net cash flow from financing activities was -$12,430,996.97, compared to $2,570,434.63 in the previous period[25] - The cash and cash equivalents increased by $27,230,272.69, contrasting with a decrease of $13,751,437.03 in the prior period[25] - The ending balance of cash and cash equivalents reached $269,405,122.68, up from $184,502,195.11 in the previous year[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥920,575,021.71, down 2.82% from the end of the previous year[6] - As of March 31, 2024, the total assets of the company amounted to RMB 920,575,021.71, a decrease from RMB 947,302,499.88 as of December 31, 2023, reflecting a decline of approximately 2.7%[15] - The company's current assets totaled RMB 762,593,605.27, down from RMB 798,830,965.69, indicating a decrease of about 4.5%[16] - Total liabilities decreased to RMB 65,924,925.32 from RMB 89,236,086.75, a reduction of approximately 26.1%[17] - The company's equity increased slightly to RMB 192,257,760.88 from RMB 191,088,940.39, reflecting a growth of about 0.6%[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 5,786[12] - The largest shareholder, Liu Jianqiang, holds 14.54% of the shares, totaling 12,810,000 shares[12] Research and Development - Research and development expenses totaled ¥10,369,812.18, accounting for 19.58% of operating revenue, a decrease of 5.00 percentage points compared to the previous year[6] - Research and development expenses were CNY 10,369,812.18 in Q1 2024, a decrease from CNY 12,318,360.85 in Q1 2023, suggesting a potential shift in R&D strategy[18] Non-Recurring Items - The net profit attributable to shareholders was ¥1,168,820.49, while the net profit after deducting non-recurring gains and losses was a loss of ¥2,197,238.40[5] - Non-recurring gains and losses amounted to ¥3,366,058.89, primarily from financial asset valuation changes[9] Efficiency and Cost Management - The company continues to focus on cost reduction and efficiency improvement, which contributed to the increase in revenue despite the net loss[10] - The company's accounts receivable decreased to RMB 67,501,577.23 from RMB 78,348,427.68, a decline of around 13.7%[15] - Inventory increased to RMB 99,216,109.29 from RMB 96,925,724.53, showing a rise of about 2.4%[16] - The company's total non-current assets increased to RMB 157,981,416.44 from RMB 148,471,534.19, indicating a growth of approximately 6.5%[16]